In June 2025, the Chinese biotechnology sector reports a dramatic growth - the Hang Seng Biotech Index increases by around 60%, significantly outpacing the 17% jump of any tech stocks in the country. This impressive surge is due to several key factors.
First, the launch of the AI model "DeepSeek-R1" in January has stimulated investments in the interaction between artificial intelligence and medical research. In addition, a number of deals with large pharmaceutical and biotechnology companies, as well as a significant number of initial public offerings (IPOs), mainly in the field of oncology therapies, contribute to this significant growth.
Analysts note how China is transforming from an "emerging market" into a "disruptive force" in the global biotechnology sector, thanks to high levels of investment and innovation in this field. This positions the country as a serious competitor to the world's leading players and strengthens the technological partnership between Chinese and international corporations.
The widespread integration of AI in biomedicine lays the foundation for new discoveries in the field of oncology, neurodegenerative diseases, and personalized medicine, further emphasizing the significance of this biotechnology boom in China.